Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: A pilot study

Cutis

Volumn 82, Issue 5, 2008, Pages 372-378

  Rendon, Marta ^a,b   Cardona, Lina M ^a   Bussear, Eric W ^a   Benitez, Adolfo L ^a   Colón, Luz E ^b   Johnson, Lori A ^b  

^a Dermatology and Aesthetic Center   (United States)

^b Galderma Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; FLUOCINOLONE ACETONIDE; GLYCOLIC ACID; GLYCOLIC ACID DERIVATIVE; HYDROQUINONE; HYDROQUINONE DERIVATIVE; RETINOIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG COMBINATION; ESTHETIC SURGERY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MELANOSIS; METHODOLOGY; MIDDLE AGED; OINTMENT; PILOT STUDY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; CHEMEXFOLIATION; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOCINOLONE ACETONIDE; FOLLOW-UP STUDIES; GLYCOLATES; HUMANS; HYDROQUINONES; MALE; MELANOSIS; MIDDLE AGED; OINTMENTS; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRETINOIN;

EID: 58149384946     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91-98.
2. Rendon MI. Utilizing combination therapy to optimize melasma outcomes. J Drugs Dermatol. 2004;3(suppl 5)S27-S34.
3. Grimes PE. Melasma. etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-1457.
4. Gupta AK, Gover MD, Nouri K, et al. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55:1048-1065.
5. Abramovits W, Barzin S, Arrazola P. A practical comparison of hydroquinone-containing products for the treatment of melasma. Skinmed. 2005;4:371-376.
6. Cestari T, Adjadj L, Hux M, et al. Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma. J Drugs Dermatol. 2007;6:153-160.
7. Menter A. Rationale for the use of topical corticosteroids in melasma. J Drugs Dermatol. 2004;3:169-174.
8. Nanda S, Grover C, Reddy BS. Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma. Dermatol Surg. 2004;30:385-389.
9. Torok HM. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream. Am J Clin Dermatol. 2006;7:223-230.
10. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67-72.
11. Torok H, Taylor S, Baumann L, et al. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol. 2005;4:592-597.
12. Torok HM, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis. 2005;75:57-62.
13. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40-48.
14. Rendon M, Berneburg M, Arellano I, et al. Treatment of melasma. J Am Acad Dermatol. 2006;54(5 suppl 2):S272-S281.
15. Sarkar R, Kaur C, Bhalla M, et al. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg. 2002;28:828-832.
16. Pérez-Bernal A, Muñoz-Pérez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol. 2000;1:261-268.
17. Wicke C, Halliday B, Allen D, et al. Effects of steroids and retinoids on wound healing. Arch Surg. 2000;135:1265-1270.
18. Toyama T, Ohura N, Kurita M, et al. Effectiveness of short-contact topical tretinoin in promoting wound healing in db/db mice. Scand J Plast Reconstr Surg Hand Surg. 2006;40:329-334.
19. Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in the treatment of melasma in dark-skinned patients. Dermatol Surg. 2004;30:756-760.